Autologous adipose‐derived stem cell for painful leg ulcers in patients with sickle cell disease. A preliminary study

Farina, Jayme Adriano; Santis, Gil Cunha De; Orellana, Maristela Delgado; Silva-Pinto, Ana Cristina; Guirro, Elaine Caldeira de Oliveira; Carvalho, Camila Silva de; Zampar, Antonio Gustavo; Coltro, Pedro Soler; Tirapeli, Luis F.; Covas, Dimas Tadeu

doi:10.1111/bjh.15891

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 26 Stem cell therapy has gained a lot of attention in recent years. 27 Two pilot studies evaluating therapies using autologous adipose-derived stem cells 28 or bone marrow mononuclear cells 29 to treat SCD ulcers showed favorable outcomes. Besides, in another genetic disease leading to severe skin ulcers, namely recessive dystrophic epidermolysis bullosa, recent phase I/II clinical trials found partial efficacy of intravenous infusions of allogeneic ABCB5 + dermal mesenchymal stem cells (MSC), 30 human umbilical cord blood-derived MSC, 31 or bone marrow-derived MSC.…”

Section: Discussionmentioning

confidence: 99%

Contribution of fetal microchimeric cells to maternal wound healing in sickle cell ulcers

et al. 2022

View full text Add to dashboard Cite

Leg ulcers are a major complication of sickle cell disease (SCD) that can cause severe complications. They are particularly challenging to treat and therapeutic innovation is needed. We previously showed that SCD ulcers display a delayed wound healing due to decreased angiogenesis. During pregnancy, fetal microchimeric cells (FMC) transferred to the mothers are recruited to maternal wounds and improve angiogenesis. After delivery, FMC persist in maternal bone marrow for decades. Here, we questioned whether fetal cells could also improve SCD ulcers in the post-partum setting. We found that skin healing was similarly improved in post-partum mice and in pregnant mice, through increased proliferation and angiogenesis. In a SCD mouse model that recapitulates SCD refractory ulcers, we showed that post-partum SCD mice healed more quickly as compared to virgin ones. This was associated with the recruitment of fetal cells in maternal wounds where they harbored markers of leukocytes and endothelial cells. In a retrospective cohort of SCD patients, we demonstrated using several parameters that ever parous SCD women had a decreased burden related to leg ulcers compared to nulliparous women. Taken together, these results indicate that healing capacities of FMC are maintained long after delivery and may be targeted to promote wound healing in post-partum SCD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Contribution of fetal microchimeric cells to maternal wound healing in sickle cell ulcers

et al. 2022

View full text Add to dashboard Cite

show abstract

“…MSCs are non-hematopoietic cells of mesodermal origin that are present in most body tissues, including bone marrow, adipose tissue, umbilical cord, and placenta, from which they can be extracted and expanded ex vivo [20,21]. MSCs can basically be used for two purposes: to regenerate tissues and organs [22,23] and for immunomodulation in immunemediated disorders, such as autoimmune diseases and aGVHD [24,25]. MSCs diminish inflammation intensity and induce immune suppression by, at least in part, suppression of the proliferation of T and NK cells and reduction of the number of pro-inflammatory monocytes.…”

Section: Introductionmentioning

confidence: 99%

Umbilical Cord Mesenchymal Stromal Cells for Steroid-Refractory Acute Graft-versus-Host Disease

et al. 2023

View full text Add to dashboard Cite

Background: Steroid-refractory acute graft-vs.-host disease (SR-aGVHD) is a complication of allogeneic hematopoietic stem cell transplantation with a dismal prognosis and for which there is no consensus-based second-line therapy. Ruxolitinib is not easily accessible in many countries. A possible therapy is the administration of mesenchymal stromal cells (MSCs). Methods: In this retrospective study, 52 patients with severe SR-aGVHD were treated with MSCs from umbilical cord (UC-MSCs) in nine institutions. Results: The median (range) age was 12.5 (0.3–65) years and the mean ± SD dose (×106/kg) was 4.73 ± 1.3 per infusion (median of four infusions). Overall (OR) and complete response (CR) rates on day 28 were 63.5% and 36.6%, respectively. Children (n = 35) had better OR (71.5% vs. 47.1%, p = 0.12), CR (48.6% vs. 11.8%, p = 0.03), overall survival (p = 0.0006), and relapse-free survival (p = 0.0014) than adults (n = 17). Acute adverse events (all of them mild or moderate) were detected in 32.7% of patients, with no significant difference in children and adult groups (p = 1.0). Conclusions: UC-MSCs are a feasible alternative therapy for SR-aGVHD, especially in children. The safety profile is favorable.

show abstract

Stem cells, organoids, and cellular therapy

Manfiolli¹,

Amaral²,

Caliári-Oliveira³

2023

Nanotechnology and Regenerative Medicine

View full text Add to dashboard Cite

Autologous adipose‐derived stem cell for painful leg ulcers in patients with sickle cell disease. A preliminary study

Cited by 3 publications

References 10 publications

Contribution of fetal microchimeric cells to maternal wound healing in sickle cell ulcers

Contribution of fetal microchimeric cells to maternal wound healing in sickle cell ulcers

Umbilical Cord Mesenchymal Stromal Cells for Steroid-Refractory Acute Graft-versus-Host Disease

Stem cells, organoids, and cellular therapy

Contact Info

Product

Resources

About